The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with a hypermutant, hypermethylated state

ABSTRACT

Coloretcal Peritoneal metastases (CPM) develop in 15% of colorectal cancers. Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS & HIPEC) is the current standard of care in selected patients with limited resectable CPM. Despite selection using known prognostic factors survival is varied and morbidity and mortality are relatively high. There is a need to improve patient selection and a paucity of research concerning the biology of isolated CPM. We aimed to determine the biology associated with transition from primary CRC to CPM and poor prognosis CPM, to identify those suitable for treatment with CRS & HIPEC and to identify targets for existing repurposed or novel treatment strategies. A cohort of patients with CPM treated with CRS & HIPEC was recruited and divided according to prognosis. Molecular profiling of the transcriptome, epigenome and genome of CPM and matched primary CRC was performed.

CPM were characterised by frequent Wnt/ β catenin negative regulator mutations, mismatch repair mutations and resulting high tumour mutational burden and dysregulation of methylation suggested by frequent TET2 mutations and mutations suggesting an immune evasive phenotype. Several novel therapies could be targeted to these frequent mutations including porcupine inhibitors, immune checkpoint inhibitors and methylation inhibitors. Here we show the molecular features associated with CPM development and with poor prognosis. Potential applications include improving patient selection for treatment and in the development of novel and personalised treatments.